Needham Reiterates Buy on Alnylam Pharmaceuticals, Maintains $200 Price Target
Portfolio Pulse from Benzinga Newsdesk
Needham analyst Joseph Stringer reiterates a Buy rating on Alnylam Pharmaceuticals (NASDAQ:ALNY) and maintains a $200 price target.

May 02, 2024 | 6:41 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Needham maintains a Buy rating and a $200 price target on Alnylam Pharmaceuticals.
The reiteration of a Buy rating and a maintained price target of $200 by a reputable analyst like Joseph Stringer from Needham is likely to instill confidence among investors and could positively influence Alnylam Pharmaceuticals' stock price in the short term. Analyst ratings, especially from well-regarded financial institutions, can significantly impact investor sentiment and stock prices.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100